Transitioning Innovation into Viable Therapeutic Candidates
May 18-20, 2015 | Parc 55 Hilton | San Francisco, CA
Alternative Language Options:
We Want Your Opinion! Help us better understand where the biggest opportunities are to advance cancer therapeutics. »Please share your insights
Pre-Show Speaker Interviews
Thank you for your interest in IBC's Bioconjugates: From Targets to Therapeutics event. To give you sneak peek at the caliber of the content presented at the conference - we would like to give you FREE access to these speaker interviews.
To Download: click the icon or the speaker name
Robert Lutz, Ph.D., Vice President, Translational Research and Development, ImmunoGen, Inc. At the event, Lutz will speak about:
The Evolution of ADCs: Lessons Learned from the Past. Where are We Going?
This talk will cover what has been learned in the two decades of ADC clinical development. It will highlight the problems encountered with current technologies and discuss where new technologies, such as site directed conjugation, alternate scaffolds, and new payloads may provide answers (or new problems!).
Carolyn R. Bertozzi, Ph.D., T.Z. and Irmgard Chu Distinguished Professor of Chemistry and Professor of Molecular and Cell Biology, UC Berkeley; Investigator, Howard Hughes Medical Institute; Senior Faculty Scientist, Lawrence Berkeley National Laboratory. At the event, Bertozzi will speak about:
Bioorthogonal Chemistries for Biomolecular Engineering
Bioorthogonal chemical reactions have such exquisite selectivity that they can be employed to modify biomolecules even within the environs of live organisms. This presentation will focus on recent developments in bioorthogonal reaction methodology and applications to the production of chemically modified protein therapeutics such as antibody-drug conjugates. The use of bioorthogonal chemical reporters for in vivo imaging and disease biomarker discovery will also be discussed.